DK0506821T3 - Hybridt protein C - Google Patents

Hybridt protein C

Info

Publication number
DK0506821T3
DK0506821T3 DK91901991.9T DK91901991T DK0506821T3 DK 0506821 T3 DK0506821 T3 DK 0506821T3 DK 91901991 T DK91901991 T DK 91901991T DK 0506821 T3 DK0506821 T3 DK 0506821T3
Authority
DK
Denmark
Prior art keywords
human
protein
modified
molecules
heavy chain
Prior art date
Application number
DK91901991.9T
Other languages
Danish (da)
English (en)
Inventor
Donald C Foster
Richard D Holly
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DK0506821T3 publication Critical patent/DK0506821T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK91901991.9T 1989-12-29 1990-12-28 Hybridt protein C DK0506821T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45885689A 1989-12-29 1989-12-29
US51537890A 1990-04-27 1990-04-27

Publications (1)

Publication Number Publication Date
DK0506821T3 true DK0506821T3 (da) 1998-03-30

Family

ID=27039137

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91901991.9T DK0506821T3 (da) 1989-12-29 1990-12-28 Hybridt protein C

Country Status (11)

Country Link
US (1) US5766921A (fr)
EP (1) EP0506821B1 (fr)
JP (1) JP3270462B2 (fr)
AT (1) ATE163048T1 (fr)
AU (1) AU7168591A (fr)
CA (1) CA2071630C (fr)
DE (1) DE69032029T2 (fr)
DK (1) DK0506821T3 (fr)
ES (1) ES2113878T3 (fr)
GR (1) GR3026414T3 (fr)
WO (1) WO1991009960A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
SV1999000067A (es) * 1998-06-01 2000-07-06 Lilly Co Eli Proteina humana c polipeptida ref. x-12279
EP1090130A1 (fr) * 1999-04-30 2001-04-11 Eli Lilly And Company Derives de proteine c
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
JP2003514545A (ja) * 1999-11-19 2003-04-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
ES2234807T3 (es) 2000-02-02 2005-07-01 Eli Lilly And Company Derivados de proteina c.
JP2003521938A (ja) 2000-02-11 2003-07-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
EP1328622A2 (fr) * 2000-10-18 2003-07-23 Maxygen Aps Molecules de proteine c ou de type proteine c activee
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
AU2002354951A1 (en) * 2001-07-19 2003-03-03 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
WO2006014839A2 (fr) * 2004-07-23 2006-02-09 The University Of Rochester La proteine c activee inhibe les effets secondaires de l'activateur de plasminogene dans le cerveau
KR20070043051A (ko) * 2004-08-17 2007-04-24 쳇엘베 베링 게엠베하 변형된 비타민 ｋ 의존적 폴리펩타이드
EP2242875A4 (fr) * 2008-01-15 2012-04-04 Univ British Columbia Protéine c rs2069915 en tant que prédicteur de réponse de survie et administration de protéine c ou d'un composé de type protéine c activé
WO2012068519A2 (fr) 2010-11-19 2012-05-24 Sirius Genomics Inc. Marqueurs associés à la réponse à une administration de la protéine c activée, et leurs utilisations
WO2023119230A1 (fr) 2021-12-22 2023-06-29 L'oreal Compositions de modulation de la voie de coagulation et de la voie de nicotinamide-adénine dinucléotide et leurs procédés d'utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4902614A (en) * 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
EP0215548B2 (fr) * 1985-06-27 1998-01-07 Zymogenetics, Inc. Expression de protéine C
EP0245949B1 (fr) * 1986-04-09 1997-10-29 Eli Lilly And Company Méthode d'utilisation des vecteurs d'expression eucaryotiques comportant les séquences stimulantes du virus BK
DK323587D0 (da) * 1987-06-25 1987-06-25 Novo Industri As Protein
JPH03501921A (ja) * 1987-05-18 1991-05-09 インテグレイテッド・ジェネティクス・インク 改良タンパク質分子、並びにその製造及び活性化方法
JP2799316B2 (ja) * 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
CA1340740C (fr) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Coexpressiondans des cellules eucaryotes
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
JP2643968B2 (ja) * 1988-02-03 1997-08-25 サントリー株式会社 Ｋｅｘ２エンドプロテアーゼ及びその製造方法
JP2728240B2 (ja) * 1988-07-26 1998-03-18 ヘキスト薬品工業株式会社 ヒトプロテインｃ変異体及びその製造方法
JPH0246296A (ja) * 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
FI85342C (fi) * 1989-02-03 1992-04-10 Tampella Oy Ab Foerfarande och anordning foer befuktning av partiklar i gasstroemningen.
EP0462207B1 (fr) * 1989-03-06 2001-02-07 Board Of Regents, The University Of Texas System T-pa mutants resistantes vis-a-vis de leurs propres inhibiteurs
ES2047946T3 (es) * 1989-08-11 1994-03-01 Zymogenetics Inc Metodos de cultivos celulares para producir proteina c activada.

Also Published As

Publication number Publication date
EP0506821A1 (fr) 1992-10-07
ATE163048T1 (de) 1998-02-15
EP0506821B1 (fr) 1998-02-04
ES2113878T3 (es) 1998-05-16
DE69032029D1 (de) 1998-03-12
CA2071630A1 (fr) 1991-06-30
GR3026414T3 (en) 1998-06-30
JP3270462B2 (ja) 2002-04-02
DE69032029T2 (de) 1998-08-20
CA2071630C (fr) 2000-02-22
JPH06502986A (ja) 1994-04-07
AU7168591A (en) 1991-07-24
WO1991009960A1 (fr) 1991-07-11
EP0506821A4 (en) 1992-11-04
US5766921A (en) 1998-06-16

Similar Documents

Publication Publication Date Title
DK0506821T3 (da) Hybridt protein C
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
FI844510A0 (fi) Ensym-resistenta immunsystemet modulerande peptider.
FI905956A (fi) Foerfarande foer producering av ett biologiskt aktivt protein.
DE69034261D1 (de) Antikörper gegen VLA-4
DE68929043T2 (de) Für androgen-rezeptor-protein kodierende dna
DE69133509D1 (de) Verfahren zur herstellung von beta-lactamen
DE60102147D1 (de) Anti-gefrier proteine, deren herstellung und verwendung
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
DE69132889T2 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
ATE343398T1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
HU895788D0 (en) Process for producing peptides and medical products containing them
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
DE69433875D1 (de) Verfahren zur präparation von humanem aktiviertem protein c
DE69113049T2 (de) Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
ATE85893T1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
BG60657B2 (en) Human recombinant interleukin-2 muteins
MX9504057A (es) Proteina que tiene actividad tpo.
DE60326157D1 (de) Verfahren zur identifizierung von modulatoren der glucoseaufnahme
ES2004438A6 (es) Un metodo para producir una proteina trombolitica